- Home
- GLRE vs TKNO Comparison
GLRE vs TKNO Comparison
Compare GLRE & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- TKNO
- Stock Information
- Founded
- GLRE 2004
- TKNO 1996
- Country
- GLRE Cayman Islands
- TKNO United States
- Employees
- GLRE N/A
- TKNO N/A
- Industry
- GLRE Property-Casualty Insurers
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- GLRE Finance
- TKNO Health Care
- Exchange
- GLRE Nasdaq
- TKNO Nasdaq
- Market Cap
- GLRE 469.0M
- TKNO 356.4M
- IPO Year
- GLRE 2007
- TKNO 2021
- Fundamental
- Price
- GLRE $13.29
- TKNO $7.06
- Analyst Decision
- GLRE
- TKNO Buy
- Analyst Count
- GLRE 0
- TKNO 1
- Target Price
- GLRE N/A
- TKNO $5.00
- AVG Volume (30 Days)
- GLRE 74.4K
- TKNO 430.4K
- Earning Date
- GLRE 05-07-2025
- TKNO 05-08-2025
- Dividend Yield
- GLRE N/A
- TKNO N/A
- EPS Growth
- GLRE N/A
- TKNO N/A
- EPS
- GLRE 1.32
- TKNO N/A
- Revenue
- GLRE $717,617,000.00
- TKNO $38,250,000.00
- Revenue This Year
- GLRE N/A
- TKNO $9.58
- Revenue Next Year
- GLRE N/A
- TKNO $15.97
- P/E Ratio
- GLRE $10.31
- TKNO N/A
- Revenue Growth
- GLRE 2.79
- TKNO 3.79
- 52 Week Low
- GLRE $11.95
- TKNO $1.16
- 52 Week High
- GLRE $15.82
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- GLRE 49.30
- TKNO 64.62
- Support Level
- GLRE $13.21
- TKNO $5.70
- Resistance Level
- GLRE $13.36
- TKNO $7.48
- Average True Range (ATR)
- GLRE 0.33
- TKNO 0.51
- MACD
- GLRE 0.03
- TKNO 0.06
- Stochastic Oscillator
- GLRE 44.58
- TKNO 76.40
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.